Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GERN
stocks logo

GERN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
50.88M
+7.03%
-0.032
-20.83%
53.85M
+35.97%
-0.034
+13.33%
60.07M
+22.51%
-0.024
+20%
Estimates Revision
The market is revising Downward the revenue expectations for Geron Corporation (GERN) for FY2025, with the revenue forecasts being adjusted by -9.04% over the past three months. During the same period, the stock price has changed by -9.29%.
Revenue Estimates for FY2025
Revise Downward
down Image
-9.04%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.83%
In Past 3 Month
Stock Price
Go Down
down Image
-9.29%
In Past 3 Month
Wall Street analysts forecast GERN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GERN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast GERN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GERN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.270
sliders
Low
4.00
Averages
4.00
High
4.00
Current: 1.270
sliders
Low
4.00
Averages
4.00
High
4.00
Goldman Sachs
initiated
$1
2025-07-10
Reason
Goldman Sachs
Price Target
$1
2025-07-10
initiated
Reason
Goldman Sachs resumed coverage of Geron with a Sell rating and $1 price target, which suggests 31% downside. The initial launch of the company's lead product and first commercial drug, Rytelo, has disappointed, and the near-term trajectory for the launch will be modest, the analyst tells investors in a research note.
Scotiabank
Greg Harrison
Outperform -> Sector Perform
downgrade
$1.50
2025-05-08
Reason
Scotiabank
Greg Harrison
Price Target
$1.50
2025-05-08
downgrade
Outperform -> Sector Perform
Reason
Scotiabank analyst Greg Harrison downgraded Geron to Sector Perform from Outperform with a $1.50 price target.
Scotiabank
Greg Harrison
Outperform -> Sector Perform
downgrade
$4
2025-05-08
Reason
Scotiabank
Greg Harrison
Price Target
$4
2025-05-08
downgrade
Outperform -> Sector Perform
Reason
Wedbush
Outperform -> NULL
downgrade
$7 -> $6
2025-05-08
Reason
Wedbush
Price Target
$7 -> $6
2025-05-08
downgrade
Outperform -> NULL
Reason
Wedbush lowered the firm's price target on Geron to $6 from $7 and keeps an Outperform rating on the shares following quarterly results. Based on the firm's discussion with management, Wedbush believes both a lack of awareness of Rytelo overall, and an apparent wariness of cytopenias associated with Rytelo treatment are key issues for uptake - the firm sees these issues as fixable with recent HCP education efforts.
HC Wainwright & Co.
Emily Bodnar
Hold
Reiterates
n/a
2025-03-12
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
n/a
2025-03-12
Reiterates
Hold
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$5
2025-03-12
Reason
Needham
Gil Blum
Price Target
$5
2025-03-12
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Geron Corp (GERN.O) is -11.79, compared to its 5-year average forward P/E of -9.01. For a more detailed relative valuation and DCF analysis to assess Geron Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.01
Current PE
-11.79
Overvalued PE
-2.21
Undervalued PE
-15.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.43
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
17.15
Undervalued EV/EBITDA
-26.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1166.61
Current PS
0.00
Overvalued PS
2654.03
Undervalued PS
-320.81
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 226.92% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GERN News & Events

Events Timeline

(ET)
2025-11-05
07:32:41
Geron projects operating expenses of $250M-$260M for FY25
select
2025-11-05
07:31:51
Geron Announces Q3 Earnings Per Share of 3 Cents, Below Consensus Estimate of 4 Cents
select
2025-10-13 (ET)
2025-10-13
16:39:43
Geron Announces Departure of COO Andrew Grethlein and CCO Jim Ziegler
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
02:13 AMNewsfilter
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
  • Clinical Progress: GT Biopharma has successfully completed the safety review for its GTB-3650 Phase 1 trial, with all six patients treated across the cohorts showing no safety or tolerability issues, indicating strong tolerability of the therapy for relapsed blood cancers.
  • Dose Advancement: The company is now advancing to Cohort 4, where patients will receive a dose of 10μg/kg/day, which is believed to be closer to the clinical efficacy threshold, potentially enhancing treatment outcomes and driving further clinical trial progress.
  • Patient Recruitment: GT Biopharma is actively screening patients for Cohort 4 and anticipates initiating dosing in the coming weeks, which will provide critical clinical data updates in the first quarter of 2026, further boosting investor confidence.
  • Technology Platform: GTB-3650 employs the company's proprietary TriKE platform technology, aiming to target cancer cells by stimulating patients' natural killer cells, demonstrating potential in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
[object Object]
Preview
9.0
01:42 AMPRnewswire
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
  • Clinical Progress: GT Biopharma has successfully completed the safety review for its GTB-3650 Phase 1 trial, with all six participants showing no safety or tolerability issues at progressively higher doses, indicating the therapy's potential in treating relapsed blood cancers.
  • Dose Advancement: The company has moved into Cohort 4, where patients will receive a dose of 10μg/kg/day, which is expected to be closer to the clinical efficacy threshold, potentially enhancing treatment outcomes and improving patient prognosis.
  • Patient Recruitment: GT Biopharma is actively screening patients for Cohort 4 and anticipates initiating dosing in the coming weeks, which will provide a more comprehensive clinical update in the first quarter of 2026.
  • Technology Platform: GTB-3650 employs the company's proprietary TriKE platform technology, aiming to target cancer cells by stimulating patients' natural killer cells, showcasing innovative potential in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
[object Object]
Preview
3.0
11-04SeekingAlpha
Geron Q3 2025 Earnings Forecast

  • Earnings Announcement: Geron (GERN) is set to release its Q3 earnings results on November 5th, with an expected EPS of -$0.04 and revenue of $53.34M.

  • EPS and Revenue Estimates: Over the past three months, EPS estimates have seen two upward revisions and no downward revisions, while revenue estimates have experienced three upward and four downward revisions.

  • Leadership Changes: Geron has announced executive leadership changes and new appointments, indicating a strategic shift within the company.

  • Sales Force Expansion: The company plans to expand its sales force by 20% and anticipates the impact of RYTELO by year-end, alongside advancing its launch plans in the EU.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Geron Corp (GERN) stock price today?

The current price of GERN is 1.27 USD — it has increased 0 % in the last trading day.

arrow icon

What is Geron Corp (GERN)'s business?

Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.

arrow icon

What is the price predicton of GERN Stock?

Wall Street analysts forecast GERN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GERN is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Geron Corp (GERN)'s revenue for the last quarter?

Geron Corp revenue for the last quarter amounts to 47.23M USD, increased 67.05 % YoY.

arrow icon

What is Geron Corp (GERN)'s earnings per share (EPS) for the last quarter?

Geron Corp. EPS for the last quarter amounts to -0.03 USD, decreased -25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Geron Corp (GERN)'s fundamentals?

The market is revising Downward the revenue expectations for Geron Corporation (GERN) for FY2025, with the revenue forecasts being adjusted by -9.04% over the past three months. During the same period, the stock price has changed by -9.29%.
arrow icon

How many employees does Geron Corp (GERN). have?

Geron Corp (GERN) has 229 emplpoyees as of December 05 2025.

arrow icon

What is Geron Corp (GERN) market cap?

Today GERN has the market capitalization of 810.71M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free